

	M07.5 - LORAZEPAM (ATIVAN)	
	MEDICATION STANDING ORDER	
Version date: 2023-07-18	Effective date: 2023-09-19 (0700 hours)	

INDICATIONS
<ul style="list-style-type: none"> Severe anxiety or agitation that is interfering with, or may interfere with, the management and safe transport of the patient

CONTRAINDICATIONS
<ul style="list-style-type: none"> True allergy to lorazepam Uncorrected hypotension Respiratory depression Central nervous system (CNS) depression

ROUTE (WORK SCOPE)	INITIAL DOSE	REPEAT DOSE
ORAL / SUBLINGUAL (PCP & ABOVE)	75 years & older - 1 mg	Once if required
	17 up to 75 years – 2 mg	
	10 up to 17 years - 1 mg	

NOTES
<ol style="list-style-type: none"> Respiratory depression can occur even after oral administration. Frequently reassess CNS and respiratory status. Providers must be prepared to manage the airway and support ventilations as required. Benzodiazepines may have more pronounced respiratory and central nervous system effects in the elderly, especially if frail or compromised.

APPROVED BY	
	
Medical Director - Provincial EMS/PT	Associate Medical Director - Provincial EMS/PT

VERSION CHANGES (refer to X08 for change tracking)
<ul style="list-style-type: none">Revised administration table presents information for scope / route / dose more clearly